Changes in immune parameters and their correction in human cases of tick-borne encephalitis.
Tick-Borne Encephalitis virus (TBEV) causes dangerous central nervous system diseases in humans. General infection leads to the development of meningitis or encephalitis, which is characterized by swelling of the brain due to inflammation. Tetracyclines may act locally to moderate inflammation in the CNS. In this study, we investigated the potential clinical benefits of administering tetracycline hydrochloride to patients hospitalized due to suspected TBEV infection presenting with fever and evidence of a recent tick bite. We also characterized an acute immune response to TBEV by profiling certain cytokines and soluble receptors in Tetracycline-treated and untreated patients. Increased serum levels of TNF-alpha, IL-1 alpha and IL-6 were found in all patients at admission. Soluble receptors presented in the serum of patients in a magnitude higher levels than the corresponding cytokines and were increasing during first weak of hospitalization. Levels of IL-10 were also rising during that period. In our study tetracycline hydrochloride acted as an immunomodulator, which was able to reduce manifestations of inflammation response during TBE course; this action led to quicker improvement of symptoms and, consequently, to a faster clinical recovery. The positive result of tetracycline hydrochloride treatment was accompanied by certain particularities in the dynamics of studied cytokines and receptors: the concentrations of IL-6, IL-1 beta, TNF-alpha dropped quicker and reached lower levels, and the concentrations of sIL-6R, IL-1RA, sTNFR1 increased faster and reached higher maximum levels in the tetracycline-treated groups. Children had the highest levels of IL-6, which were not neurotoxic.
Atrasheuskaya
A V
AV
State Research Centre of Virology and Biotechnology (Vector), Koltsovo, Novosibirsk Region, Russia.
Fredeking
T M
TM
Ignatyev
G M
GM
D000328:Adult; D000368:Aged; D002648:Child; D016207:Cytokines / Q000097:blood*; D004669:Encephalitis Viruses, Tick-Borne; D004675:Encephalitis, Tick-Borne / Q000188:drug therapy / Q000276:immunology*; D005260:Female; D006801:Humans; D007375:Interleukin-1 / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D008297:Male; D008875:Middle Aged; D011500:Protein Synthesis Inhibitors / Q000627:therapeutic use*; D018121:Receptors, Cytokine / Q000097:blood*; D012044:Regression Analysis; D013752:Tetracycline / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis
D016207:Cytokines; D007375:Interleukin-1; D015850:Interleukin-6; D011500:Protein Synthesis Inhibitors; D018121:Receptors, Cytokine; D014409:Tumor Necrosis Factor-alpha; D013752:Tetracycline